

May 24, 2023

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 read with circular CIR/CFD/CMD/4/2015 dated September 9, 2015 – Outcome of meeting of Board of Directors

This is to inform you that the Board of Directors of the Company at its meeting held today has:

- (i) Recommended a final dividend of Rs. 9.25 (462.50%) per equity share of face value of Rs. 2 for the year 2022-23. The dividend, if declared, will be remitted/ dividend warrants will be dispatched on or after 10 days from date of Annual General Meeting.
- (ii) The Board considered and approved sub-division/split of existing equity shares of face value Rs. 2/- each of the Company to equity shares of face value Re. 1/- each of the Company, subject to regulatory/statutory approvals as may be required and the approval of the shareholders of the Company. The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed herewith as **Annexure 1**.

Further, the Board recommended consequential amendment in the Share Capital Clause of the Memorandum of Association of the Company, subject to approval of the Shareholders of the Company. The details of alteration to Memorandum of Association is provided in **Annexure 2.**



The meeting of the Board of Directors commenced at 2.32 p.m. and concluded at 4.02 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully, For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary



Annexure 1

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S.	Particulars	Disclosure	
No.			
1	Split ratio	1:2	
		Existing equity shares of face value Rs. 2/- each of the Company shall be sub-divided to equity shares of face value Re. 1/- each of the Company.	
2	Rationale of the split	To enhance the liquidity of Company's shares in stock market, to make it more affordable and to broad base shareholding by small investors.	
3	Pre and post share capital – authorized, paid-up and subscribed		

	Pre sub-division			Post sub-division		
				No. of equity		Share capital
	shares	(in Rs.)	(in Rs.)	shares	(in Rs.)	(in Rs.)
Authorised						
share capital	10,15,00,000	2	20,30,00,000	20,30,00,000	1	20,30,00,000
Issued,						
Subscribed						
and Paid-up						
share capital	7,73,77,584	2	15,47,55,168	15,47,55,168	1	15,47,55,168

4	Expected time of	Approximately two months from the date of receipt of
	completion	shareholders' approval.



5	Class of shares which are sub-divided	Equity shares. (the Company has only one class of shares, viz. equity shares)
6	Number of shares of each class pre and post-split	Please refer to our response at S. No. 3 above
7	Number of shareholders who did not get any shares in consolidation and their pre- consolidation shareholding	Not Applicable

Annexure 2

The Board of Directors of the Company at its meeting held on May 24, 2023 has, subject to approval of the shareholders, approved the alteration to the Memorandum of Association of the Company as under:

V. "The Authorised share capital of the Company is Rs. 20,30,00,000/- (Rupees Twenty Crores Thirty Lakhs only) divided into 20,30,00,000 (Twenty Crores Thirty Lakhs only) equity shares of Re 1/- (Rupee one only) each."